Advertisement

Tumor Biology

, Volume 37, Issue 8, pp 10883–10891 | Cite as

Decreased expression of Siglec-8 associates with poor prognosis in patients with gastric cancer after surgical resection

  • Yifan Cao
  • Hao Liu
  • Heng Zhang
  • Chao Lin
  • Ruochen Li
  • Weijuan Zhang
  • Zhenbin Shen
  • Jiejie Xu
Original Article

Abstract

The expression of sialic acid-binding Ig-like lectin (Siglec) family has been detected in many malignant tumors and correlated with patient outcomes. The present study aims to investigate the prognostic value of Siglec-8 expression and refine current risk stratification system in patients with gastric cancer. Two independent sets of patients (n = 78; n = 356, respectively) with gastric cancer from Zhongshan Hospital were enrolled into this study. The expression of Siglec-8 was detected by immunohistochemistry. Cox regression analysis was used to assess the prognostic value of Siglec-8 expression and clinical outcomes. A novel molecular prognostic stratification system combining intratumoral Siglec-8 expression with TNM stage was determined by means of receiver operating characteristic analysis. Multivariate Cox regression analysis identified that intratumoral Siglec-8 low expression was an independent prognostic factor for dismal overall survival of patients with gastric cancer. Incorporating intratumoral Siglec-8 expression into the current TNM staging system showed more accuracy for predicting prognosis of patients with gastric cancer. Our study suggested that intratumoral Siglec-8 expression was an independent prognostic factor for overall survival of patients with gastric cancer. Incorporating Siglec-8 expression level into current TNM staging system might add more comprehensive prognostic information for patients with gastric cancer and lead to a more precise risk stratification system for predicting clinical outcomes.

Keywords

Gastric cancer Siglec-8 Prognosis Biomarker Overall survival 

Notes

Acknowledgments

This study was funded by grants from the National Basic Research Program of China (2012CB822104), National Key Projects for Infectious Diseases of China (2012ZX10002012-007 and 2016ZX10002018-008), National Natural Science Foundation of China (31100629, 31270863, 81372755, 31470794, 81401988, 81402082, 81402085, 81471621, 81472227, 81472376, 31570803, 81501999, and 81572352), and Program for New Century Excellent Talents in University (NCET-13-0146). All these study sponsors have no roles in the study design, in the collection, analysis, and interpretation of data.

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Bhayal AC, Krishnaveni D, Rao KPR, Kumar AR, Jyothy A, Nallari P, et al. Significant Association of Interleukin4 Intron 3 VNTR Polymorphism with Susceptibility to Gastric Cancer in a South Indian Population from Telangana. PLoS ONE. 2015;10(9):e0138442.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol. 2006;12(1):17–20.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med. 1995;333(1):32–41.CrossRefPubMedGoogle Scholar
  4. 4.
    Rivera F, Vega-Villegas ME, López-Brea MF. Chemotherapy of advanced gastric cancer. Cancer Treat Rev. 2007;33(4):315–24.CrossRefPubMedGoogle Scholar
  5. 5.
    Stock M, Otto F. Gene deregulation in gastric cancer. Gene. 2005;360(1):1–19.CrossRefPubMedGoogle Scholar
  6. 6.
    Zhang H, Wang X, Xu J, Sun Y. Notch1 activation is a poor prognostic factor in patients with gastric cancer. Br J Cancer. 2014;110(9):2283–90.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Crocker PR CE, Filbin M, Gordon S, Jones Y, Kehrl JH, Kelm S et al. Siglecs: a family of sialic-acid binding lectins. Glycobiology. 1998;8(2).Google Scholar
  8. 8.
    Floyd H, Ni J, Cornish AL, Zeng Z, Liu D, Carter KC, et al. Siglec-8: a novel eosinophil-specific member of the immunoglobulin superfamily. J Biol Chem. 2000;275(2):861–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Hudson SA, Herrmann H, Du J, Cox P, Haddad E-B, Butler B, et al. Developmental, malignancy-related, and cross-species analysis of eosinophil, mast cell, and basophil siglec-8 expression. J Clin Immunol. 2011;31(6):1045–53.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kiwamoto T, Kawasaki N, Paulson JC, Bochner BS. Siglec-8 as a drugable target to treat eosinophil and mast cell-associated conditions. Pharmacol Ther. 2012;135(3):327–36.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Bochner BS, Alvarez RA, Mehta P, Bovin NV, Blixt O, White JR, et al. Glycan array screening reveals a candidate ligand for Siglec-8. J Biol Chem. 2005;280(6):4307–12.CrossRefPubMedGoogle Scholar
  12. 12.
    Bochner BS. Siglec-8 on human eosinophils and mast cells, and Siglec-F on murine eosinophils, are functionally related inhibitory receptors. Clin Exp Allergy. 2009;39(3):317–24.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wang S, Chen X, Wei A, Yu X, Niang B, Zhang J. α2,6-linked sialic acids on N-glycans modulate the adhesion of hepatocarcinoma cells to lymph nodes. Tumor Biol. 2015;36(2):885–92.CrossRefGoogle Scholar
  14. 14.
    Zhang P, Lu X, Tao K, Shi L, Li W, Wang G, et al. Siglec-10 is associated with survival and natural killer cell dysfunction in hepatocellular carcinoma. J Surg Res. 2015;194(1):107–13.CrossRefPubMedGoogle Scholar
  15. 15.
    O’Reilly MK, Paulson JC. Siglecs as targets for therapy in immune cell mediated disease. Trends Pharmacol Sci. 2009;30(5):240–8.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Tuscano JM, Kato J, Pearson D, Xiong C, Newell L, Ma Y, et al. CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy. Cancer Res. 2012;72(21):5556–65.CrossRefPubMedGoogle Scholar
  17. 17.
    Zhu X-D, Zhang J-B, Zhuang P-Y, Zhu H-G, Zhang W, Xiong Y-Q, et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 2008;26(16):2707–16.CrossRefPubMedGoogle Scholar
  18. 18.
    Weichert W, Röske A, Gekeler V, Beckers T, Ebert MPA, Pross M et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. The Lancet Oncol. 9(2):139-48.Google Scholar
  19. 19.
    He H, Chen W, Wang X, Wang C, Liu F, Shen Z, et al. Snail is an independent prognostic predictor for progression and patient survival of gastric cancer. Cancer Sci. 2012;103(7):1296–303.CrossRefPubMedGoogle Scholar
  20. 20.
    Herrmann H, Cerny-Reiterer S, Gleixner KV, Blatt K, Herndlhofer S, Rabitsch W, et al. CD34(+)/CD38(−) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin. Haematologica. 2012;97(2):219–26.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Bochner BS, Schleimer RP. Mast cells, basophils, and eosinophils: distinct but overlapping pathways for recruitment. Immunol Rev. 2001;179(1):5–15.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Department of Biochemistry and Molecular Biology, School of Basic Medical SciencesFudan UniversityShanghaiChina
  2. 2.Department of General Surgery, Zhongshan HospitalFudan UniversityShanghaiChina
  3. 3.Department of Immunology, School of Basic Medical SciencesFudan UniversityShanghaiChina

Personalised recommendations